A new look at the neonate's clinical presentation after in utero exposure to antidepressants in late pregnancy

Journal of Clinical Psychopharmacology

Volumn 28, Issue 3, 2008, Pages 334-339

  Boucher, Nina ^a,b   Bairam, Aida ^a,c   Beaulac Baillargeon, Louise ^a,b,c  

^a Université Laval   (Canada)

^b Faculty of Pharmacy   (Canada)

^c UNIVERSITÉ LAVAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALPRAZOLAM; AMITRIPTYLINE; ANTIDEPRESSANT AGENT; BROMAZEPAM; CITALOPRAM; CLONAZEPAM; FLUOXETINE; FLUVOXAMINE; LORAZEPAM; OLANZAPINE; PAROXETINE; RISPERIDONE; SERTRALINE; TRAZODONE; VENLAFAXINE; NEUROLEPTIC AGENT; SEROTONIN UPTAKE INHIBITOR;

ALERTNESS; ARTICLE; DEPRESSION; DIAPHORESIS; DIARRHEA; DISEASE CLASSIFICATION; FACTORIAL ANALYSIS; FEEDING DISORDER; FEMALE; FOOD REGURGITATION; HUMAN; HYPERREFLEXIA; HYPERTHERMIA; HYPOREFLEXIA; INSOMNIA; IRRITABILITY; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; MUSCLE RIGIDITY; MUSCLE TONE; NEWBORN; PRENATAL DRUG EXPOSURE; PRIORITY JOURNAL; RESTLESSNESS; RISK ASSESSMENT; SEIZURE; SIDE EFFECT; SNEEZING; SUCKING; SWEATING; SYMPTOM; TACHYPNEA; TREMOR; VOMITING; ADULT; AROUSAL; CESAREAN SECTION; CHEMICALLY INDUCED DISORDER; CHILD BEHAVIOR; COMPARATIVE STUDY; DRUG COMBINATION; DRUG EFFECT; INTRAUTERINE GROWTH RETARDATION; NEUROLOGIC EXAMINATION; PREGNANCY; PREGNANCY COMPLICATION; PREMATURITY; REGRESSION ANALYSIS; RETROSPECTIVE STUDY; RISK; SEROTONIN SYNDROME; WITHDRAWAL SYNDROME;

ADULT; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; ANTIPSYCHOTIC AGENTS; AROUSAL; CESAREAN SECTION; DEPRESSIVE DISORDER; DRUG THERAPY, COMBINATION; FACTOR ANALYSIS, STATISTICAL; FEMALE; FETAL GROWTH RETARDATION; HUMANS; INFANT BEHAVIOR; INFANT, NEWBORN; INFANT, PREMATURE, DISEASES; MALE; MUSCLE TONUS; NEONATAL ABSTINENCE SYNDROME; NEUROLOGIC EXAMINATION; PREGNANCY; PREGNANCY COMPLICATIONS; REGRESSION ANALYSIS; RETROSPECTIVE STUDIES; RISK; SEROTONIN SYNDROME; SEROTONIN UPTAKE INHIBITORS;

EID: 51449106586     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/JCP.0b013e318173aa2e     Document Type: Article

References (20)

1. Boyer EW, Shannon M. The serotonin syndrome. N Engl J Med. 2005; 352:1112-1120.
2. Isbister GK, Buckley NA, Whyte IM. Serotonin toxicity: a practical approach to diagnosis and treatment. Med J Aust. 2007;187:361-365.
3. Isbister GK, Buckley NA. The pathophysiology of serotonin toxicity in animals and humans: implications for diagnosis and treatment. Clin Neuropharm. 2005;28:205-214.
4. Black K, Shea C, Dursun S, et al. Selective serotonin inhibitor discontinuation syndrome: proposed diagnostic criteria. J Psychiatry Neurosci. 2000;26:255-261.
5. Price JS, Waller PC, Wood SM, et al. A comparison of the postmarketing safety of four selective serotonin re-uptake inhibitors including the investigation of symptoms occurring on withdrawal. Br J Clin Pharmacol. 1996;42:757-763.
6. Shelton RC. The nature of the discontinuation syndrome associated with antidepressant drugs. J Clin Psychiatry. 2006;67(suppl 4):3-7.
7. Sanz EJ, De-las-Cuevas C, Kiuru A, et al. Selective serotonin reuptake inhibitors in pregnant women and neonatal withdrawal syndrome: a database analysis. Lancet. 2005;365:482-487.
8. Kallen B. Neonate characteristics after maternal use of antidepressants in late pregnancy. Arch Pediatr Adolesc Med. 2004;158:312-316.
9. Levinson-Castiel R, Merlob P, Linder N, et al. Neonatal abstinence syndrome after in utero exposure to selective serotonin reuptake inhibitors in term infants. Arch Pediatr Adolesc Med. 2006;160:173-176.
10. Rampono J, Proud S, Hackett LP, et al. A pilot study of newer antidepressant concentrations in cord and maternal serum and possible effects in the neonate. Int J Neuropsychopharmacol. 2004;7:329-334.
11. Laine K, Heikkinen T, Ekblad U, et al. Effects of exposure to selective serotonin reuptake inhibitors during pregnancy on serotonergic symptoms in newborns and cord blood monoamine and prolactin concentrations. Arch Gen Psychiatry. 2003;60:720-726.
12. Zeskind PS, Stephens LE. Maternal selective serotonin reuptake inhibitor use during pregnancy and newborn neurobehavior. Pediatrics. 2004;113:368-375.
13. Jaiswal S, Coombs RC, Isbister GK. Paroxetine withdrawal in a neonate with historical and laboratory confirmation. Eur J Pediatr. 2003;162: 723-724.
14. Ferriero DM. Neonatal brain injury. N Engl J Med. 2004;351:1985-1995.
15. Beaulac-Baillargeon L, Boucher N. Neonatal Adverse Reactions After In Utero Exposure to Selective Serotonin Reuptake Inhibitors (SSRI): Still Controversial. Arch Pediatr Adolesc Med. 2006;160:855-856.
16. Blier P, Tremblay P. Physiologic mechanisms underlying the antidepressant discontinuation syndrome. J Clin Psychiatry. 2006:67(suppl 4): 8-13.
17. Taylor NC, Li A, Nattie EE. Medullary serotonergic neurones modulate the ventilatory response to hypercapnia, but not hypoxia in conscious rats. J Physiol. 2005;566(Pt 2):543-557.
18. Ramos E, Oraichi D, Rey E. et al. Prevalence and predictors of antidepressant use in a cohort of pregnant women. BJOG. 2007;114: 1055-1064.
19. O'Keane V, Marsh MS. Depression during pregnancy. BMJ. 2007; 334:1003-1005.
20. Dombrowski MP. Outcomes of pregnancy in asthmatic women. Immunol Allergy Clin North Am. 2006;26:81-92.